A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition

Inclusion Criteria: * Patients aged 20 and older * Patients are expected to require PN for more than 5 days * Patients who voluntarily signed the consent form Exclusion Criteria: * Patients are expected difficult to survive more than 5 days * Pregnant or breast-feeding women * BMI \> 30 kg/m2 * Patients with severe blood coagulation disorders * Patients with congenital amino acid metabolism disorders * Patients with acute shock * Patients with uncontrollable diabetes mellitus * Patients with hemophage syndrome * Patients with hypopotassemia (K \< 3.0mEq/L) * Patients having the history of myocardial infarction * Patients reported the following laboratory value * fasting TG \> 250mg/dl, TC \> 300mg/dl * ALT/AST ≥ 2×ULN, Bilirubin ≥ 3mg/dl (Exception : patients with periampullary carcinoma including biliary tract or pancreas) * Creatinine ≥ 1.5mg/dl * Ca \> 11.2mg/dl, Na ≥ 145mEq/L, Mg ≥ 2.1mEq/L, K ≥ 5.5mEq/L * Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug * Patients having the history of drug or alcohol abuse * General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, cardiac decompensation * Patients are in unstable conditions * Patients with difficult peripheral intravenous * Patients with parenteral nutrition within 7 days prior to start of the trial * Participation in another clinical study with an investigational drug or an investigational medical device within 28 days prior to start of study * Patients judged to be unsuitable for this trial by investigators